● Recruiting

Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients

Condition: Systemic Lupus Erythematosus · Sponsor: RenJi Hospital

PhaseNA

Planned participants176

Who can joinAll sexes, 18 Years to 70 Years

Healthy volunteersNo

About this study

This study is a randomized, double-blind, placebo-controlled single-center clinical trial. The aim of this study is to investigate the efficacy and safety of low-dose telitacicept for prevention of flares in SLE patients with low disease activity.

This description comes directly from the study's public registry record.

Talk to the study team

Ting Li · +8613916927066 · leeting007@163.com

Shuang Ye · ye_shuang2000@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Ren Ji Hospital

Shanghai, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06394063